Last reviewed · How we verify
Melatonin 10 MG
Melatonin 10 MG, marketed by Cairo University, is a sleep aid currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that could help maintain market position. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Melatonin 10 MG |
|---|---|
| Also known as | (Melatonin 10 mg - Puritan's Pride premium company), circadian, N-acetyl-5-methoxy tryptamine, melatonin, Melatonin Lek-AM 10mg |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Melatonin fOr CHronic bAck Pain (The MOCHA Trial) (PHASE3)
- Melatonin on Post Operative Pain After CS (NA)
- Preoperative Melatonin to Decrease Analgesia Usage After Third Molar Surgery (PHASE2)
- Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients (PHASE2)
- Melatonin for Glycemic Control in Gestational Diabetes Mellitus (PHASE2)
- RECOVER-SLEEP: Platform Protocol (PHASE2)
- Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin (NA)
- Melatonin vs Midazolam in Children Undergoing Tonsillectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melatonin 10 MG CI brief — competitive landscape report
- Melatonin 10 MG updates RSS · CI watch RSS
- Cairo University portfolio CI